Patents by Inventor Alberto BALDI

Alberto BALDI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
    Patent number: 9388239
    Abstract: Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab when administered at the same dosage.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 12, 2016
    Assignees: Consejo Nacional De Investigation Cientifica, LABORATORIO Pablo Cassana SRL
    Inventors: Alberto Baldi, Adrián Daniel Góngora, Alejandro Gustavo Mladovan
  • ANTI-HUMAN VEGF ANTIBODIES WITH UNUSUALLY STRONG BINDING AFINITY TO HUMAN VEGF-A AND CROSS REACTIVITY TO HUMAN VEGF-B
    Publication number: 20150315270
    Abstract: Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 5, 2015
    Inventors: Alberto BALDI, Adrián Daniel Góngora, Alejandro Gustavo Mladovan